Company Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.925 ^USD	-4.10%		+10.80%	+55.99%

Apr. 22	Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26	MT
Apr. 05	Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	CI

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Companyâs portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Number of employees: 27

Managers	Title	Age	Since
Jacqueline Zummo FOU	Founder	43	17-10-31
Jesse Shefferman FOU	Founder	52	17-10-31
Patrick Fabbio DFI	Director of Finance/CFO	56	23-01-29
Justine O'Malley IRC	Investor Relations Contact	-	20-11-30
Hannah Fry AUD	Comptroller/Controller/Auditor	34	20-03-31
Mary J. Grendell LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Luke Beshar CHM	Chairman	65	18-09-30
Gregory Sargen BRD	Director/Board Member	59	19-10-31
Roger Garceau BRD	Director/Board Member	70	18-12-31
Barry Flannelly BRD	Director/Board Member	66	20-07-22
Richard Levy BRD	Director/Board Member	66	19-11-30
Michael Solomon BRD	Director/Board Member	54	18-04-30
Cynthia Smith BRD	Director/Board Member	55	20-12-31
Jane Huang BRD	Director/Board Member	51	21-06-08
Jesse Shefferman FOU	Founder	52	17-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	7,991	0	0	83.41 %
Stock B	1	11,433,837	9,536,478 ( 83.41 %)	0

Name	Equities	%	Valuation
Opaleye Management, Inc. 23.55 %	2,692,594	23.55 %	11 M $
RA Capital Management LP 16.62 %	1,900,000	16.62 %	8 M $
Citadel Advisors LLC 10.53 %	1,203,943	10.53 %	5 M $
Jesse Shefferman 8.257 %	944,064	8.257 %	4 M $
Heights Capital Management, Inc. 5.251 %	600,380	5.251 %	2 M $
Randall Marshall 5.122 %	585,600	5.122 %	2 M $
Vanguard Global Advisers LLC 3.740 %	427,612	3.740 %	2 M $
Boxer Capital LLC 1.830 %	209,227	1.830 %	839 000 $
Baker Bros. Advisors LP 1.746 %	199,671	1.746 %	800 681 $
Luke Beshar 1.732 %	198,000	1.732 %	793 980 $

Protara Therapeutics, Inc.

345 Park Avenue South 3rd Floor

10010, New York

http://www.protaratx.com

address Protara Therapeutics, Inc.(TARA)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.925 USD

Average target price

27.8 USD

Spread / Average Target

+850.43%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PROTARA THERAPEUTICS, INC.	+55.99%	60.19M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.64%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.38%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs